propriate (eg, those with a history of reproductive cancer or demonstrated intolerance to HRT), and no publicly subsidised therapeutic options are available in Australia for such women. The aim of this study was to assess the cost-effectiveness of raloxifene in preventing osteoporotic fractures when HRT is inappropriate. METHODS: A Markov model was developed to compare raloxifene with no drug therapy in patients who are unable to use HRT. Separate analyses were performed for those who are intolerant of HRT and those unsuitable for HRT due to a history of reproductive cancer (with a consequent greater baseline risk of breast cancer). Relative efficacy assumptions in the model were taken from randomised controlled trials and the published literature. Primary outcomes included vertebral fractures, non-vertebral fractures and breast cancer in a cohort with a low bone mineral density and an average age of 65 years. The model ran for a period of 30 years, contained nine discrete states and produced cost per quality-adjusted lifeyear (QALY) values. Limited memory was incorporated into the model by separating each fracture health state into two states, representing a first year and then subsequent years after fracture. RESULTS: The incremental cost per QALY gained with raloxifene compared with no therapy was $33,539 in those who are intolerant of HRT and $29,780 per QALY in patients with a history of reproductive cancer. Extensive sensitivity analyses indicated the results remained robust. CONCLUSIONS: Raloxifene is a cost-effective therapy to reduce fracture risk in postmenopausal women unsuitable for HRT. Continuity is a key treatment success factor to reduce relapse and hospitalisation rates of schizophrenic patients. Atypical antipsychotics with daily oral administration are associated with improved efficacy, tolerability and compliance compared with older, conventional neuroleptics. Similarly, conventional depots have shown to reduce the risk of relapse over oral conventional. The novel long-acting risperidone, administered intramuscularly once every two weeks, is the first long-acting formulation of an atypical antipsychotic. OBJECTIVES: To assess the cost-effectiveness of long-acting risperidone versus oral olanzapine and haloperidol decanoate in recently diagnosed schizophrenic patients. METHODS: A cost-effectiveness analysis is considered. Main assumption is that compliance improvement, thanks to a longacting formulation leads to an increased efficacy. A decision tree model was built with a time horizon of 2 years. A French payers perspective was adopted. Outcome probabilities and cost estimates were based on published data, and supplemented with expert opinion. Only direct medical costs were considered. Effectiveness measures were relapse-free patients and patients maintained on the same treatment for 2 years. RESULTS: 76.30% of the patients receiving long-acting risperidone remained relapse-free, compared with 69.60% with olanzapine and 47.70% with haloperidol decanoate. Of the patients treated with long-acting risperidone, 82.7% remained successfully on treatment for 2 years, compared with 74.80% and 57.30% for patients treated with olanzapine and haloperidol decanoate respectively. Total direct cost per patient over 2 years were €13,168 with risperidone, €13,280 with olanzapine, and €16,910 with haloperidol decanoate. Long-acting risperidone was the dominant strategy in each case and remained dominant strategy in sensitivity analyses. CONCLUSION: The model indicates that treatment with long-acting risperidone reduces relapses, improves continuity of treatment, and is associated with decreased total direct medical costs over two years, when compared with oral olanzapine and haloperidol decanoate. 
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